Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 401

1.

The role of positive selection in hepatitis C virus.

Cuevas JM, Gonzalez M, Torres-Puente M, Jiménez-Hernández N, Bracho MA, García-Robles I, González-Candelas F, Moya A.

Infect Genet Evol. 2009 Sep;9(5):860-6. doi: 10.1016/j.meegid.2009.05.007. Epub 2009 May 20.

PMID:
19463971
2.

Genetic variability in hepatitis C virus and its role in antiviral treatment response.

Torres-Puente M, Cuevas JM, Jiménez-Hernández N, Bracho MA, García-Robles I, Wrobel B, Carnicer F, Del Olmo J, Ortega E, Moya A, González-Candelas F.

J Viral Hepat. 2008 Mar;15(3):188-99. doi: 10.1111/j.1365-2893.2007.00929.x.

PMID:
18233992
3.

NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.

Bouzgarrou N, Hassen E, Mahfoudh W, Gabbouj S, Schvoerer E, Ben Yahia A, Ben Mami N, Triki H, Chouchane L.

J Med Virol. 2009 Dec;81(12):2021-8. doi: 10.1002/jmv.21641.

PMID:
19856481
4.

[Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin].

Veillon P, Payan C, Gaudy C, Goudeau A, Lunel F.

Pathol Biol (Paris). 2004 Nov;52(9):505-10. French.

PMID:
15531113
5.

Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-alpha preparations.

Durante Mangoni E, Forton DM, Ruggiero G, Karayiannis P.

J Med Virol. 2003 May;70(1):62-73.

PMID:
12629645
6.

Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment.

Torres-Puente M, Cuevas JM, Jiménez-Hernández N, Bracho MA, García-Robles I, Carnicer F, del Olmo J, Ortega E, Moya A, González-Candelas F.

J Med Virol. 2008 Feb;80(2):247-53.

PMID:
18098147
7.

Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.

Muñoz de Rueda P, Casado J, Patón R, Quintero D, Palacios A, Gila A, Quiles R, León J, Ruiz-Extremera A, Salmerón J.

J Virol. 2008 Jul;82(13):6644-53. doi: 10.1128/JVI.02231-07. Epub 2008 Apr 30.

8.

Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.

Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, Trepo C, Zoulim F.

J Med Virol. 2004 Sep;74(1):41-53.

PMID:
15258967
10.

Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.

Hofmann WP, Zeuzem S, Sarrazin C.

J Clin Virol. 2005 Feb;32(2):86-91. Review.

PMID:
15653410
11.
12.

The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India.

Goyal A, Hofmann WP, Hermann E, Traver S, Hissar SS, Arora N, Blum HE, Zeuzem S, Sarrazin C, Sarin SK.

Med Microbiol Immunol. 2007 Mar;196(1):11-21. Epub 2006 Sep 6.

PMID:
16955308
13.

Contribution of insertions and deletions to the variability of hepatitis C virus populations.

Torres-Puente M, Cuevas JM, Jiménez-Hernández N, Bracho MA, García-Robles I, Carnicer F, del Olmo J, Ortega E, Moya A, González-Candelas F.

J Gen Virol. 2007 Aug;88(Pt 8):2198-203.

PMID:
17622623
14.
15.

Using evolutionary tools to refine the new hypervariable region 3 within the envelope 2 protein of hepatitis C virus.

Torres-Puente M, Cuevas JM, Jiménez-Hernández N, Bracho MA, García-Robles I, Wrobel B, Carnicer F, del Olmo J, Ortega E, Moya A, González-Candelas F.

Infect Genet Evol. 2008 Jan;8(1):74-82. Epub 2007 Oct 25.

PMID:
18063425
16.

Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.

Sarrazin C, Bruckner M, Herrmann E, Rüster B, Bruch K, Roth WK, Zeuzem S.

Virology. 2001 Oct 10;289(1):150-63.

17.

Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response.

Cuevas JM, Torres-Puente M, Jiménez-Hernández N, Bracho MA, García-Robles I, Carnicer F, Olmo JD, Ortega E, Moya A, González-Candelas F.

J Viral Hepat. 2008 Aug;15(8):578-90. doi: 10.1111/j.1365-2893.2008.00991.x. Epub 2008 May 4.

PMID:
18466261
18.

The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism.

Tsai YH, Kuang WF, Lu TY, Kao JH, Lai MY, Liu CJ, Chen PJ, Hwang LH.

J Hepatol. 2008 Dec;49(6):899-907. doi: 10.1016/j.jhep.2008.06.030. Epub 2008 Sep 16.

PMID:
18842320
19.

Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.

Berg T, Mas Marques A, Höhne M, Wiedenmann B, Hopf U, Schreier E.

Hepatology. 2000 Dec;32(6):1386-95.

PMID:
11093746
20.

Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha.

Gerotto M, Dal Pero F, Sullivan DG, Chemello L, Cavalletto L, Polyak SJ, Pontisso P, Gretch DR, Alberti A.

J Viral Hepat. 1999 Sep;6(5):367-72.

PMID:
10607252

Supplemental Content

Support Center